Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 2
2007 2
2013 1
2014 5
2015 1
2016 1
2017 4
2018 3
2019 1
2020 2
2021 2
2022 2
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials.
Rosenstock J, Marquard J, Laffel LM, Neubacher D, Kaspers S, Cherney DZ, Zinman B, Skyler JS, George J, Soleymanlou N, Perkins BA. Rosenstock J, et al. Among authors: soleymanlou n. Diabetes Care. 2018 Dec;41(12):2560-2569. doi: 10.2337/dc18-1749. Epub 2018 Oct 4. Diabetes Care. 2018. PMID: 30287422 Clinical Trial.
Renal hemodynamic effects of sodium-glucose cotransporter 2 inhibitors in hyperfiltering people with type 1 diabetes and people with type 2 diabetes and normal kidney function.
van Bommel EJM, Lytvyn Y, Perkins BA, Soleymanlou N, Fagan NM, Koitka-Weber A, Joles JA, Cherney DZI, van Raalte DH. van Bommel EJM, et al. Among authors: soleymanlou n. Kidney Int. 2020 Apr;97(4):631-635. doi: 10.1016/j.kint.2019.12.021. Kidney Int. 2020. PMID: 32200854 Free article. No abstract available.
Kidney Effects of Empagliflozin in People with Type 1 Diabetes.
Cherney DZI, Bjornstad P, Perkins BA, Rosenstock J, Neubacher D, Marquard J, Soleymanlou N. Cherney DZI, et al. Among authors: soleymanlou n. Clin J Am Soc Nephrol. 2021 Nov;16(11):1715-1719. doi: 10.2215/CJN.07700621. Epub 2021 Sep 17. Clin J Am Soc Nephrol. 2021. PMID: 34535454 Free PMC article. No abstract available.
Patient preferences for newer oral therapies in type 2 diabetes.
Savarese G, Sharma A, Pang C, Wood R, Soleymanlou N. Savarese G, et al. Among authors: soleymanlou n. Int J Cardiol. 2023 Jan 15;371:526-532. doi: 10.1016/j.ijcard.2022.09.009. Epub 2022 Sep 10. Int J Cardiol. 2023. PMID: 36096275 Free article.
Exploring Patient Preferences for Adjunct-to-Insulin Therapy in Type 1 Diabetes.
Perkins BA, Rosenstock J, Skyler JS, Laffel LM, Cherney DZ, Mathieu C, Pang C, Wood R, Kinduryte O, George JT, Marquard J, Soleymanlou N. Perkins BA, et al. Among authors: soleymanlou n. Diabetes Care. 2019 Sep;42(9):1716-1723. doi: 10.2337/dc19-0548. Epub 2019 Jun 8. Diabetes Care. 2019. PMID: 31177179 Free PMC article.
25 results